Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine and Temozolomide in Recurrent Glioma
NCT05634707Phase 1Active, not recruiting
- Sponsor
- Duke University
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluoxetine in malignant glioma (3 arms), sponsored by Duke University. Primary endpoint: Change in LAMP1 expression in tumor samples at 1 month. Started Aug 2023; status: active, not recruiting.
02
Drugs
fluoxetine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT05634707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634707.